Type 2 diabetes mellitus and cardiovascular risk; what the pharmacotherapy can change through the epigenetics.
作者： Pavlina A. Andreeva–Gateva , Ivelina D. Mihaleva , Ivanka I. Dimova
DOI: 10.1080/00325481.2019.1681215
关键词: Diabetes mellitus 、 Pharmacotherapy 、 Bioinformatics 、 Metabolic syndrome 、 Obesity 、 Insulin resistance 、 Type 2 Diabetes Mellitus 、 Medicine 、 Dyslipidemia 、 Epigenetics
摘要: Diabetes mellitus and cardiovascular diseases are part of the metabolic syndrome share similar risk factors, including obesity, arterial hypertension, dyslipidemia. Atherosclerosis insulin resistance contribute to development diseases, subclinical inflammation is observed in both conditions. There many proofs about connection between epigenetic factors different diabetes diseases. Interestingly, recent studies show that at least some anti-diabetic drugs, as well blockers renin-angiotensin-aldosterone system (RAAS), exert effects aside from their hypoglycemic antihypertensive functions, respectively. More needed discover other positive medications established through mechanisms find out more role
sci-hub.se 参考文章(163)
, Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. ,vol. 31, pp. 1007- 1014 ,(2008) , 10.2337/DC07-1868
Effects of intensive glucose lowering in type 2 diabetes The New England Journal of Medicine. ,vol. 358, pp. 2545- 2559 ,(2008) , 10.1056/NEJMOA0802743
X. Jiang, F. Zhang, Q. Ning, Losartan reverses the down-expression of long noncoding RNA-NR024118 and Cdkn1c induced by angiotensin II in adult rat cardiac fibroblasts. Pathologie Biologie. ,vol. 63, pp. 122- 125 ,(2015) , 10.1016/J.PATBIO.2015.04.001
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine. ,vol. 358, pp. 2560- 2572 ,(2008) , 10.1056/NEJMOA0802987
JJ McMurray, RR Holman, SM Haffner, MA Bethel, B Holzhauer, TA Hua, Y Belenkov, M Boolell, JB Buse, BM ....Rutten GEHM.....Califf RM. Buckley, AR Chacra, FT Chiang, B Charbonnel, CC Chow, MJ Davies, P Deedwania, P Diem, D Einhorn, V Fonseca, GR Fulcher, Z Gaciong, S Gaztambide, T Giles, E Horton, H Ilkova, T Jenssen, SE Kahn, H Krum, M Laakso, LA Leiter, NS Levitt, V Mareev, F Martinez, C Masson, T Mazzone, E Meaney, R Nesto, CY Pan, R Prager, SA Raptis, GEHM Rutten, H Sandstroem, F Schaper, A Scheen, O Schmitz, I Sinay, V Soska, S Stender, G Tamas, G Tognoni, J Tuomilehto, AS Villamil, J Vozar, RM Califf, Effect of valsartan on the incidence of diabetes and cardiovascular events. The New England Journal of Medicine. ,vol. 362, pp. 1477- 1490 ,(2010) , 10.1056/NEJMOA1001121
Eva Aumueller, Marlene Remely, Hanna Baeck, Berit Hippe, Helmut Brath, Alexander G. Haslberger, Interleukin-6 CpG Methylation and Body Weight Correlate Differently in Type 2 Diabetes Patients Compared to Obese and Lean Controls Journal of Nutrigenetics and Nutrigenomics. ,vol. 8, pp. 26- 35 ,(2015) , 10.1159/000381714
Gerald V Denis, Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation. Discovery Medicine. ,vol. 10, pp. 489- 499 ,(2010)
Alexander C West, David A Bechtold, None, The cost of circadian desynchrony: Evidence, insights and open questions BioEssays. ,vol. 37, pp. 777- 788 ,(2015) , 10.1002/BIES.201400173
Matthew A. Sparks, Steven D. Crowley, Susan B. Gurley, Maria Mirotsou, Thomas M. Coffman, Classical Renin‐Angiotensin System in Kidney Physiology Comprehensive Physiology. ,vol. 4, pp. 1201- 1228 ,(2014) , 10.1002/CPHY.C130040
G. Ruvkun, MOLECULAR BIOLOGY: Glimpses of a Tiny RNA World Science. ,vol. 294, pp. 797- 799 ,(2001) , 10.1126/SCIENCE.1066315